Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 10/20 | 0.66 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 6/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.48 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.48 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.48 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.48 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.48 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.48 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.48 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.48 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9547692 | 0.79 | ACHE (1.00) | ACHETSHRALDH1A1CYP1A2KCNH2 | |
| SCHEMBL5086180 | 0.79 | ACHE (0.55) | ACHETSHRALDH1A1CYP1A2KCNH2 | |
| SCHEMBL10620451 | 0.79 | ACHE (0.61) | ACHETSHRALDH1A1CYP1A2KCNH2 | |
| SCHEMBL5083430 | 0.77 | ACHE (0.66) | ACHETSHRALDH1A1CYP1A2KCNH2 | |
| 7-Hydroxytacrine SCHEMBL9547668 | 0.73 | ACHE (1.00) | ACHETSHRALDH1A1CYP1A2KCNH2 | |
| SCHEMBL8781795 | 0.71 | ACHE (0.62) | ACHETSHRALDH1A1CYP1A2KCNH2 | |
| SCHEMBL9547653 | 0.71 | ACHE (1.00) | ACHETSHRALDH1A1CYP1A2KCNH2 | |
| Hydrochloric Acid SCHEMBL9547702 | 0.70 | ACHE (0.97) | ACHETSHRALDH1A1CYP1A2KCNH2 | |
| SCHEMBL10654276 | 0.70 | ACHE (0.53) | ACHETSHRALDH1A1CYP1A2KCNH2 | |
| SCHEMBL4782557 | 0.69 | ACHE (0.53) | ACHETSHRALDH1A1CYP1A2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008021210-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| EP-0589900-A1 | ALZHEIMER'S DISEASE TREATMENT WITH TACRINE METABOLITES | INSTITUTE OF PSYCHIATRY (GB) | 1994-04-06 | — | — | EP | disclosed |
| WO-1992022534-A1 | ALZHEIMER'S DISEASE TREATMENT WITH TACRINE METABOLITES | MARCHBANKS ROGER MICHAEL (GB) | 1992-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | ACHE 16/4885TSHR 4669/4885ALDH1A1 2348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.